|
|
| (66 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| |
| {{Malihas}}
| |
| {{CMG}}; {{AE}} {{Sapan}}
| |
|
| |
|
| __NOTOC__
| | ====Acute Sinusitis==== |
| {{Endocarditis}}
| | [[Acute (medical)|Acute]] sinusitis is usually precipitated by an earlier [[upper respiratory tract infection]], generally of [[virus|viral]] origin. |
| | Virally damaged surface tissues are then colonized by [[bacteria]], most commonly ''[[Haemophilus influenzae]]'', ''[[Streptococcus pneumoniae]]'', ''[[Moraxella catarrhalis]]'' and ''[[Staphylococcus aureus]]''. Other [[bacterial]] [[pathogen]]s include other [[streptococci]] [[species]], [[Anaerobic organism|anaerobic bacteria]] and, less commonly, [[gram negative]] bacteria. |
| | Another possible cause of sinusitis can be dental problems that affect the maxillary sinus. |
| | [[Acute (medical)|Acute]] episodes of sinusitis can also result from [[fungus|fungal]] invasion. |
| | These [[infection]]s are most often seen in [[patient]]s with [[diabetes]] or other [[immunodeficiency|immune deficiencies]] (such as [[AIDS]] or [[transplant]] [[patient]]s on anti-rejection medications) and can be life threatening. In type I diabetes, ketoacidosis causes sinusitis by [[Mucormycosis]]. |
|
| |
|
| {{CMG}}; '''Associate Editors-in-Chief:''' {{CZ}}
| |
|
| |
|
| ==Overview== | | ====Chronic Sinusitis==== |
| Early valve surgery should be scheduled when there is [[heart failure]] due to the valve dysfunction, left-sided infective endocarditis due to ''[[Staphylococcus aureus]]'', fungal or highly resistant organisms, or a [[heart block]], annular or aortic [[abscess]] or destructive lesions. Other indications include persistent [[bacteremia]] or [[fever]] 5 to 7 following the initiation of the [[antibiotic]]s, relapse of the infection depsite a complete course of antibiotics in [[prosthetic valve]] endocarditis when no portal of infection can be identified, recurrent emboli and persistent vegetations despite [[antibiotic therapy]], and mobile vegetations with a length more than 10 mm in native valve endocarditis. Surgical removal of the [[valve]] is necessary in patients who fail to clear micro-organisms from their blood in response to [[antibiotic]] therapy, or in patients who develop [[cardiac failure]] resulting from destruction of a [[valve]] by [[infection]]. A removed valve is usually replaced with an artificial valve which may either be mechanical (metallic) or obtained from an animal such as a pig; the latter are termed bioprosthetic valves.<ref name= Baddour>{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A.| title = Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = 3167-84 | year = 2005 | id = PMID 15956145 }}</ref> Surgical treatment of endocarditis involves excision of all infected [[valve]] tissue, drainage and debridement of [[abscess]] cavities, repair or replacement of damaged valves, and repair of any associated pathology such as [[fistula]]s or septal defects.<ref name= Baddour>{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A.| title = Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = 3167-84 | year = 2005 | id = PMID 15956145}}</ref>
| | Chronic sinusitis is a complicated spectrum of diseases that share chronic inflammation of the sinuses in common. The causes are multifactorial and may include allergy, environmental factors such as dust or pollution, bacterial infection, and/or fungus (either allergic, infective or reactive). Non allergic factors such as [[Vasomotor rhinitis]] can also cause chronic sinus problems. |
|
| |
|
| ==Surgery==
| | Symptoms include: [[Nasal congestion]]; facial pain; [[headache]]; [[fever]]; general [[malaise]]; thick green or yellow [[Rhinorrhea|discharge]]; feeling of facial 'fullness' worsening on bending over; aching teeth. |
|
| |
|
| ===Indications===
| | Very rarely, chronic sinusitis can lead to [[anosmia]], the inability to [[olfaction|smell]] or detect odors. |
| Indications for surgical debridement of vegetations and infected perivalvular tissue, with valve replacement or repair as needed are listed below:<ref name= Baddour>{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A.| title = Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = 3167-84 | year = 2005 | id = PMID 15956145 }}</ref>
| |
| # Moderate to severe [[congestive heart failure]] due to valve dysfunction
| |
| # Unstable valve prosthesis
| |
| # Uncontrolled infection for > 1–3 week despite maximal antimicrobial therapy
| |
| # Persistent [[bacteremia]]
| |
| #[[endocarditis|Fungal endocarditis]]
| |
| # Relapse after optimal therapy in a prosthetic valve
| |
| # Vegetation in Situ
| |
| # Prosthetic valve [[endocarditis]] with perivalvular invasion
| |
| # [[Endocarditis]] caused by [[Pseudomonas aeruginosa]] or other gram-negative bacilli that has not responded after 7–10 days of maximal antimicrobial therapy
| |
| # Perivalvular extension of infection and abscess formation
| |
| # [[Staphylococcal]] infection of prosthesis
| |
| # Persistent [[fever]] (culture negative)
| |
| # Large vegetation (>10 mm is associated with an increased risk of embolism)
| |
| # Relapse after optimal therapy in a native valve
| |
| # Vegetations that obstruct the valve orifice
| |
| # Onset of [[AV block]]
| |
|
| |
|
| ==2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease (DO NOT EDIT)==
| | In a small number of cases, chronic [[maxillary]] sinusitis can also be brought on by the spreading of bacteria from a dental infection. |
|
| |
|
| ===Indications for Surgery for Native Valve Endocarditis (DO NOT EDIT)<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume= 129 | issue= 23 | pages= 2440-92 | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852 }} </ref>===
| | Attempts have been made to provide a more consistent nomenclature for subtypes of chronic sinusitis. A task force for the American Academy of Otolaryngology - Head and Neck Surgery / Foundation along with the Sinus and Allergy Health Partnership broke Chronic Sinusitis into two main divisions, Chronic Sinusitis without polyps and Chronic Sinusitis with polyps (also often referred to as Chronic Hyperplastic Sinusitis). Recent studies which have sought to further determine and characterize a common pathologic progression of disease have resulted in an expansion of proposed subtypes. Many patients have demonstrated the presence of [[Eosinophil granulocyte|eosinophils]] in the mucous lining of the nose and paranasal sinuses. As such the name Eosinophilic Mucin RhinoSinusitis (EMRS) has come into being. Cases of EMRS may be related to an allergic response, but allergy is often not documentable, resulting in further subcategorization of allergic and non-allergic EMRS. |
|
| |
|
| {|class="wikitable"
| | A more recent, and still debated, development in chronic sinusitis is the role that [[fungus]] may play. Fungus can be found in the nasal cavities and sinuses of most patients with sinusitis, but can also be found in healthy people as well. It remains unclear if fungus is a definite factor in the development of chronic sinusitis and if it is, what the difference may be between those who develop the disease and those who do not. |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Decisions about timing of surgical intervention should be made by a multispecialty Heart Valve Team of [[cardiology]], cardiothoracic surgery, and [[infectious disease]] specialists (301). ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']]) <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Early surgery (during initial hospitalization before completion of a full therapeutic course of [[antibiotics]]) is indicated in patients with IE who present with [[valve]] dysfunction resulting in symptoms of [[heart failure]] (342-347). ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']]) <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' Early surgery (during initial hospitalization before completion of a full therapeutic course of [[antibiotic]]s) is indicated in patients with left-sided IE caused by ''[[Staphylococcus aureus]]'', fungal, or other highly resistant organisms (347-354). ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']]) <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.''' Early surgery (during initial hospitalization before completion of a full therapeutic course of [[antibiotics]]) is indicated in patients with IE complicated by[[ heart block]], annular or aortic [[abscess]], or destructive penetrating lesions (347, 355-359). ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']]) <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''5.''' Early surgery (during initial hospitalization before completion of a full therapeutic course of [[antibiotics]]) for IE is indicated in patients with evidence of persistent [[infection]] as manifested by persistent bacteremia or [[fever]]s lasting longer than 5 to 7 days after onset of appropriate antimicrobial therapy (347, 352, 353, 360-362). ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']]) <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''6.''' Surgery is recommended for patients with prosthetic valve endocarditis and relapsing [[infection]] (defined as recurrence of bacteremia after a complete course of appropriate [[antibiotics]] and subsequently negative blood cultures) without other identifiable source for portal of [[infection]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']]) <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''7.''' Complete removal of [[pacemaker]] or [[defibrillator]] systems, including all leads and the generator, is indicated as part of the early management plan in patients with IE with documented infection of the device or leads (363-366). ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']]) <nowiki>"</nowiki>
| |
| | |
| | |
| |}
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| |
| | |
| |-
| |
| | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Complete removal of [[pacemaker]] or [[defibrillator]] systems, including all leads and the generator, is reasonable in patients with valvular IE caused by ''[[Staphylococcus aureus]]'' or fungi, even without evidence of device or lead [[infection]] (363-366). ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])<nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' Complete removal of [[pacemaker]] or [[defibrillator]] systems, including all leads and the generator, is reasonable in patients undergoing valve surgery for valvular IE. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']]) <nowiki>"</nowiki>
| |
| | |
| |-
| |
| | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.'''Early surgery (during initial hospitalization before completion of a full therapeutic course of [[antibiotics]]) is reasonable in patients with IE who present with recurrent emboli and persistent vegetations despite appropriate [[antibiotic]] therapy (302, 367, 368). ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])<nowiki>"</nowiki>
| |
| | |
| |}
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]
| |
| |-
| |
| | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Early surgery (during initial hospitalization before completion of a full therapeutic course of antibiotics) may be considered in patients with native valve endocarditis who exhibit mobile vegetations greater than 10 mm in length (with or without clinical evidence of embolic phenomenon) (302, 367, 368). ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])<nowiki>"</nowiki>
| |
| |}
| |
| | |
| ==2008 AHA/ACC Guideline for the Management of Patients With Prosthetic Valve Endocarditis (DO NOT EDIT)==
| |
| ===Indications for Surgery for Prosthetic Valve Endocarditis (DO NOT EDIT) <ref name="pmid18820172">{{cite journal |author=Bonow RO, Carabello BA, Chatterjee K, ''et al.'' |title=2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons |journal=Circulation |volume=118 |issue=15 |pages=e523–661 |year=2008 |month=October |pmid=18820172 |doi=10.1161/CIRCULATIONAHA.108.190748 |url=}}</ref>===
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Consultation with a [[cardiac surgeon]] is indicated for patients with [[infective endocarditis]] of a [[artificial heart valve|prosthetic valve]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Surgery is indicated for patients with [[infective endocarditis]] of a [[artificial heart valve|prosthetic valve]] who present with [[heart failure]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])<nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' Surgery is indicated for patients with [[infective endocarditis]] of a [[artificial heart valve|prosthetic valve]] who present with [[dehiscence]] evidenced by cine [[fluoroscopy]] or [[echocardiography]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])<nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.''' Surgery is indicated for patients with [[infective endocarditis]] of a [[artificial heart valve|prosthetic valve]] who present with evidence of increasing [[obstruction]] or worsening [[regurgitation (circulation)|regurgitation]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''5.''' Surgery is indicated for patients with [[infective endocarditis]] of a [[artificial heart valve|prosthetic valve]] who present with [[complication (medicine)|complications]] (e.g., [[abscess]] formation). ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki>
| |
| |}
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]]
| |
| |-
| |
| | bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Routine surgery is not indicated for patients with uncomplicated [[infective endocarditis]] of a [[artificial heart valve|prosthetic valve]] caused by first infection with a sensitive organism. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki>
| |
| |}
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| |
| | |
| |-
| |
| | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Surgery is reasonable for patients with [[infective endocarditis]] of a [[artificial heart valve|prosthetic valve]] who present with evidence of persistent [[bacteremia]] or recurrent [[emboli]] despite appropriate antibiotic treatment. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' Surgery is reasonable for patients with [[infective endocarditis]] of a [[artificial heart valve|prosthetic valve]] who present with relapsing [[infection]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki>
| |
| |}
| |
| | |
| ==Principles of Surgical Treatment of Endocarditis==
| |
| Surgical treatment of endocarditis includes:<ref name= Baddour>{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A.| title = Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = 3167-84 | year = 2005 | id = PMID 15956145 }}</ref>
| |
| *Excision of all infected [[valve]] tissue
| |
| *Drainage and debridement of [[abscess]] cavities
| |
| *Repair or replacement of damaged valves
| |
| *Repair of any associated pathology such as septal defect, [[fistula]]s
| |
| | |
| ==Aortic Valve - Surgical Options==
| |
| If the [[infection]] is limited to the leaflets, then the [[aortic valve]] should be replaced. If the infection extends to the anulus or beyond, then the infected tissues should be debrided. Any abscesses should be drained and the aortic root should be replaced.
| |
| | |
| ==Atrioventricular Valve - Surgical Options==
| |
| If the infection is limited to the leaflets, then the vegetations should be excised, perforations should be repaired, and a reduction annuloplasty should be performed. If the infection extends to the anulus or beyond, then a valve replacement should be performed, and abscesses should be debrided and obliterated. In some cases the tricuspid valve may be excised.
| |
| | |
| ==Surgical Outcomes==
| |
| Operative mortality is 15 - 20%. The development of an infection of a prosthetic valve during operation for [[endocarditis|native valve endocarditis]] is 4%, it is higher (12 - 16%) if active [[endocarditis]] is present at the time of the surgery. Late survival at 5 years for [[endocarditis|native valve endocarditis]] is 70 - 80% and for [[endocarditis|prosthetic valve endocarditis]] is 50 - 80%.<ref name= Baddour>{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A.| title = Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = 3167-84 | year = 2005 | id = PMID 15956145 }}</ref>
| |
| | |
| ==2008 and Incorporated 2006 ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease (DO NOT EDIT) <ref name="pmid18820172">{{cite journal |author=Bonow RO, Carabello BA, Chatterjee K, ''et al.'' |title=2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons |journal=Circulation |volume=118 |issue=15 |pages=e523–661 |year=2008 |month=October |pmid=18820172 |doi=10.1161/CIRCULATIONAHA.108.190748 |url=}}</ref>==
| |
| | |
| ===Intraoperative Assessment (DO NOT EDIT) <ref name="pmid18820172">{{cite journal |author=Bonow RO, Carabello BA, Chatterjee K, ''et al.'' |title=2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons |journal=Circulation |volume=118 |issue=15 |pages=e523–661 |year=2008 |month=October |pmid=18820172 |doi=10.1161/CIRCULATIONAHA.108.190748 |url=}}</ref>===
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Intraoperative [[transesophageal echocardiography]] is recommended for valve surgery for [[infective endocarditis]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])<nowiki>"</nowiki>
| |
| |}
| |
| | |
| {{WH}}
| |
| {{WS}}
| |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Emergency medicine]]
| |
| [[Category:Cardiology]]
| |
| [[Category:Infectious disease]]
| |
| [[Category:Intensive care medicine]]
| |
| [[Category:Up-To-Date]]
| |
| | |
| {{WH}}
| |
| {{WS}}
| |